Is Metoclopramide Safe in Pregnancy
Status
cautionReason
Official sources do not show increased birth-defect risk, but late-pregnancy/neonatal effects are possible; use only if needed.
Drug Information
Safe Amount
Dosage must be determined by your provider based on individual risk/benefit. Official labeling warns against use longer than 12 weeks except rare cases.
Effects
- Pregnancy
- Not expected to increase birth-defect risk above background. Official labels note no increased risk in published pregnancy studies.
- Mother
- May cause movement side effects, including extrapyramidal symptoms and tardive dyskinesia, especially with longer use.
- Baby
- Crosses the placenta. Use during delivery may cause extrapyramidal signs and methemoglobinemia in the newborn.
Trimester Notes
- 1st Trimester
- No increased birth-defect risk was reported in official pregnancy summaries, but data are still limited.
- 2nd Trimester
- Generally used when needed; use the lowest effective dose for the shortest time under provider guidance.
- 3rd Trimester
- Use caution near delivery. Newborn may need monitoring for extrapyramidal signs and methemoglobinemia.
Risk-Benefit Note
For pregnancy nausea and vomiting, metoclopramide may be used when symptoms are hard to control and the benefit outweighs the risk. Do not stop or continue it without your prescriber’s advice.
Conditions & Warnings
- Consult OB/GYN or prescriber
- Nausea and vomiting in pregnancy
- Hyperemesis gravidarum
- Use only if benefits outweigh risks
Alternatives
- Doxylamine-pyridoxine
- Provider-recommended non-drug measures for nausea
- Other anti-sickness medicines with fewer side effects, if your clinician recommends them
References
- FDA Reglan (metoclopramide) label
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017854s062lbl.pdf - NHS metoclopramide pregnancy, breastfeeding and fertility
https://www.nhs.uk/medicines/metoclopramide/pregnancy-breastfeeding-and-fertility-while-taking-metoclopramide/ - MotherToBaby Metoclopramide fact sheet
https://www.ncbi.nlm.nih.gov/books/NBK582840/
Black Box Warning: Tardive dyskinesia risk with prolonged use; avoid treatment longer than 12 weeks except rare cases.